These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22532260)

  • 21. DYT6 in Japan-genetic screening and clinical characteristics of the patients.
    Miyamoto R; Koizumi H; Morino H; Kawarai T; Maruyama H; Mukai Y; Miyashiro A; Sako W; Izumi Y; Kawakami H; Kaji R
    Mov Disord; 2014 Feb; 29(2):278-80. PubMed ID: 24227593
    [No Abstract]   [Full Text] [Related]  

  • 22. The current use of botulinum toxin.
    Mahant N; Clouston PD; Lorentz IT
    J Clin Neurosci; 2000 Sep; 7(5):389-94. PubMed ID: 10942658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A survey about the accessibility to botulinum toxin therapy for dystonia].
    Mezaki T; Hayashi A; Nakase H; Hasegawa K
    No To Shinkei; 2006 Mar; 58(3):219-24. PubMed ID: 16629446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Botulinum toxins for pain].
    Soinila S; Haanpää M
    Duodecim; 2011; 127(22):2425-30. PubMed ID: 22238920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic fatigue syndrome is commonly diagnosed in patients with Ehlers-Danlos syndrome hypermobility type/joint hypermobility syndrome.
    Castori M; Celletti C; Camerota F; Grammatico P
    Clin Exp Rheumatol; 2011; 29(3):597-8. PubMed ID: 21722506
    [No Abstract]   [Full Text] [Related]  

  • 27. Botulinum toxin: historical perspective and potential new indications.
    Jankovic J; Brin MF
    Muscle Nerve Suppl; 1997; 6():S129-45. PubMed ID: 9826986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatigue is a frequent and clinically relevant problem in Ehlers-Danlos Syndrome.
    Voermans NC; Knoop H; van de Kamp N; Hamel BC; Bleijenberg G; van Engelen BG
    Semin Arthritis Rheum; 2010 Dec; 40(3):267-74. PubMed ID: 19878973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin.
    Brin MF; Blitzer A; Stewart C
    Adv Neurol; 1998; 78():237-52. PubMed ID: 9750921
    [No Abstract]   [Full Text] [Related]  

  • 30. [Blepharospasm: treatment with botulinum toxin].
    Barbosa ER; Silva HC; Haddad MS; Bittar MS
    Rev Hosp Clin Fac Med Sao Paulo; 1996; 51(6):220-3. PubMed ID: 9239894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Botulinum toxin--from threat to cure].
    Odergren T; Lennerstrand G; Lindestad PA; Hertegård S; Borg J
    Lakartidningen; 1996 Apr; 93(17):1619-24. PubMed ID: 8667769
    [No Abstract]   [Full Text] [Related]  

  • 32. The moving ear syndrome: a focal dyskinesia.
    Chaudhuri KR; Leigh PN; Gibb WR; Pye IF
    J Neurol Neurosurg Psychiatry; 1996 Jan; 60(1):106. PubMed ID: 8558136
    [No Abstract]   [Full Text] [Related]  

  • 33. Jaw-opening dystonia: Quality of life after botulinum toxin injections.
    Charous SJ; Comella CL; Fan W
    Ear Nose Throat J; 2011 Feb; 90(2):E9. PubMed ID: 21328222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current classifications of dystonies, treatment strategy].
    Zalialova ZA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(3):85-9. PubMed ID: 23612417
    [No Abstract]   [Full Text] [Related]  

  • 35. [Parkinsonian dystonia].
    Dowsey-Limousin P
    Rev Neurol (Paris); 2003 Oct; 159(10 Pt 1):928-31. PubMed ID: 14615683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of dystonia.
    Thenganatt MA; Jankovic J
    Neurotherapeutics; 2014 Jan; 11(1):139-52. PubMed ID: 24142590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. THAP1 mutations are infrequent in spasmodic dysphonia.
    Groen JL; Yildirim E; Ritz K; Baas F; van Hilten JJ; van der Meulen FW; Langeveld TP; Tijssen MA
    Mov Disord; 2011 Aug; 26(10):1952-4. PubMed ID: 21538522
    [No Abstract]   [Full Text] [Related]  

  • 38. Botulinum toxin in movement disorders.
    Papapetropoulos S; Singer C
    Semin Neurol; 2007 Apr; 27(2):183-94. PubMed ID: 17390263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of cervical dystonia with botulinum toxin.
    Jankovic J
    Mov Disord; 2004 Mar; 19 Suppl 8():S109-15. PubMed ID: 15027062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Botulinum toxin in the treatment of spasticity].
    Arriola-Arellano E; Chacón J; Alvarez-López M; Balbuena-García M; Fuentes-Pradera J; Vicente-Baz D
    Rev Neurol; 2006 Feb 16-28; 42(4):250-1. PubMed ID: 16521066
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.